Pharmaceutical Ozagrel Hydrochloride Raw Powder Ozagrel HCl Purity Ozagrel

• Powder: Powder
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung Ozagrel
• Product Name: Ozagrel
• Name: Ozagrel Powder
• Appearance: White Powde
• Color: White
• Specific: COA
• Grade: Pharmaceutical Grade
• Assay: 99%
• Application: Pharmaceutical
• Test Method: HPLC Tlc
• CAS: 82571-53-7
• Mf: C13h12n2o2
• MW: 228.25
• Melting Point: 223-224
• Boiling Point: 468.0
• Shelf Life: 2 Years
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical Ozagrel Hydrochloride Raw Powder Ozagrel Hcl Purity Ozagrel

Product Description

Product Details

Product Name	Ozagrel
Purity	99%
Origin	China
Application	Research
Character	Powder
Appearance	White Powder

Mr Gray and clopidogrel, helo he thiazole, aspirin enteric-coated metformin hydrochloride is at present, the commonly used platelet aggregation inhibitor, belongs to the coagulation evil alkyl epoxy enzymes (TXA2) inhibitors antithrombotic drugs, initially by Japanese ono pharmaceutical industry co., LTD and Kissei pharmaceutical industry research and development success, approed for sale in Japan in 1988. At present, the main domestic manufacturers are Liaoning Dandong Medical innovation pharmaceutical co., LTD., Shandong Luo Xin Pharmaceutical Co., LTD., Changchun Jingyou Pharmaceutical Co., LTD., Dalian Meruo Pharmaceutical Co., LTD., Shenyang Cheshi Pharmaceutical Co., LTD., Hainan Biicalbook Kai Pharmaceutical Co., LTD., Changchun Haobang Pharmaceutical Co., Ltd. and Shandong Hualu Pharmaceutical Co., LTD. Modern medicine has proved that platelets play an important role in the process of arteriosclerosis and thrombosis, and effective regulation of platelets can get twice the result with half the effort for diseases caused by vascular lumen stenosis, blood embolus and circulatory system occlusion. At present, the main platelet agglutination inhibitors in clinical use are cytase (TXA2) inhibitors, phosphodiesterase (PDE) inhibitors, adenosine diphosphate (ADP) receptor blockers, platelet fibrinogen blockers and other drugs.

Application&Function

Potent thromboxane synthase inhibitor. By inhibiting thromboxane synthase, thromboxane A, (TXA2) and prostacyclin (PGl2) production can be reduced in the body to counter platelet aggregation and vasospasm Chemicalbook of cerebrovascular, while cycloxidase and other arachidonic acid metabolic enzymes have almost no effect. It is clinically used for ameliorating cerebral spasm after subcobweb hemorrhage, cerebral ischemia symptoms accompanying cerebral spasm, and movement disorders accompanying acute cerebral thrombosis.

Specification